Nanobody-Enhanced Chimeric Antigen Receptor T-Cell Therapy: Overcoming Barriers in Solid Tumors with VHH and VNAR-Based Constructs

Investigators highlight the benefits of utilizing single domain antibody in CAR-T therapy, particularly in targeting tumor antigens, and explore development strategies that could advance the field.